[NP_P11] Poster Session 11

[NP-P11-1] The Efficacy and Safety of Lurasidone in Acutely Psychotic Subjects with Schizophrenia：A 6-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (JEWEL Study)

^○Masaomi IYO¹, Jun ISHIGOOKA², Masatoshi NAKAMURA³, Reiko SAKAGUCHI⁴, Keisuke OKAMOTO⁵, Tadashi NOSAKA⁶, Teruhiko HIGUCHI ^{7, 8} (1. Department of Psychiatry, Graduate School of Medicine, Chiba University, Japan, 2. Institute of CNS Pharmacology, Japan, 3. Data Science, Sumitomo Dainippon Pharma Co., Ltd., Japan, 4. Clinical Research, Sumitomo Dainippon Pharma Co., Ltd., Japan, 5. Clinical Operations, Sumitomo Dainippon Pharma Co., Ltd., Japan, 6. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd., Japan, 7. Japan Depression Center, Japan, 8. The National Center of Neurology and Psychiatry, Japan)